EUVIMEDEUVIMED entdecken
Crossref

Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting

Giulio Trapè, Gioia De Angelis, Marco Morucci, Michela Tarnani, Cinzia De Gregoris, Ambra Di Veroli, Valentina Panichi, Giuseppe Topini, Loredana Bassi, Raffaella Isidori, Monica Poscente, Vincenza Innocenti und 13 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Giulio Trapè und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Aim of the study was to evaluate the role of a Domiciliary Hematologic Care Unit (DHCU) compared to standard DH setting in the active frontline treatment with hypomethylating agents (HMAs) +/− venetoclax of frail patients with acute myelogenous leukemia/high‐risk myelodysplastic syndromes (AML/HR‐MDS).

Methods

All patients with newly diagnosed AML/HR‐MDS unfit for intensive care and treated frontline with HMAs from January 2010 to April 2021 were retrospectively included.

Results

Among 112 patients (62 AML/50 HR‐MDS), 69 (61.6%) were treated in a standard DH setting and 43 (38.4%) were followed by DHCU, allocated to DH or DHCU by responsible physician. Overall response rate was 29/69 (42.0%) in DH versus 19/43 (44.1%) in DHCU ( p = .797). Median response duration was 8.7 months (95%CI 7.0–10.3) in DH versus 13.0 months (95%CI 8.3–17.6) in DHCU ( p = .460). Infections were also equally reported. Median overall survival of patients treated in DH was 13.7 months (95%CI 9.9–17.4) compared to 13.0 months (95%CI 6.7–19.3) of patients managed by DHCU ( p = .753).

Conclusions

Home care management of HMA is feasible and effective, with results similar to standard DH setting: this approach is thus adequate to offer active therapies in frail patients with AML/HR‐MDS considered up to now ineligible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansTreatment OutcomeRetrospective StudiesHospitalsAzacitidine

Stichwörter der Autor:innen

acute myeloid leukemiahigh-risk myelodysplastic syndromeshome care managementhypomethylating agents

Substanzen

Azacitidine

Autor:innen und Institutionen

  • Hematology Unit-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Laboratory of Immunophenotyping-ASL Viterbo, Belcolle Hospital, Viterbo, Italy.
  • Laboratory of Medical Genetics-ASL Viterbo, Ospedale Belcolle, Viterbo, Italy.

ORCID-Profile: Roberto Latagliata

Zitieren

APA

Trapè, G., De Angelis, G., Morucci, M., Tarnani, M., De Gregoris, C., Di Veroli, A., Panichi, V., Topini, G., Bassi, L., Isidori, R., Poscente, M., Innocenti, V., Cippitelli, E. E., Talucci, R., Bertelli, S., Crocicchia, A., Lippi, A., Pezzuti, G., Fuschino, M., …, & Latagliata, R. (2023). Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting. European Journal of Haematology. https://doi.org/10.1111/ejh.14012

Vancouver

Trapè G, De Angelis G, Morucci M, Tarnani M, De Gregoris C, Di Veroli A, et al. Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting. European Journal of Haematology. 2023. doi:10.1111/ejh.14012

BibTeX
@article{Trap2023,
  author = {Trapè, Giulio and De Angelis, Gioia and Morucci, Marco and Tarnani, Michela and De Gregoris, Cinzia and Di Veroli, Ambra and Panichi, Valentina and Topini, Giuseppe and Bassi, Loredana and Isidori, Raffaella and Poscente, Monica and Innocenti, Vincenza and Cippitelli, Elisa Emanueli and Talucci, Roberta and Bertelli, Silvia and Crocicchia, Alessandra and Lippi, Annalisa and Pezzuti, Giulia and Fuschino, Michela and Randi, Raffaella and Mastini, Cristina and Ciambella, Silvia and Pessina, Gloria and Montanaro, Marco and Latagliata, Roberto},
  title = {Treatment in patients with acute myeloid leukemia/high‐risk myelodysplastic syndrome with hypomethylating agents: Day‐hospital management compared to home care setting},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14012}
}
Kostenlos starten →